|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0009402,
umls-concept:C0016360,
umls-concept:C0022277,
umls-concept:C0069717,
umls-concept:C0178602,
umls-concept:C0205179,
umls-concept:C0205195,
umls-concept:C0243095,
umls-concept:C0585332,
umls-concept:C0677667,
umls-concept:C0679729,
umls-concept:C1511237,
umls-concept:C1518578,
umls-concept:C1522326,
umls-concept:C1550436,
umls-concept:C1705509,
umls-concept:C1710133,
umls-concept:C2603343
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2000-10-6
|
|
pubmed:abstractText |
To determine the maximum tolerated dose of oxaliplatin (L-OHP) given as a two-hour infusion followed by raltitrexed (Tomudex [TOM]) administered as a 15-min infusion on day 1, and bolus 5-fluorouracil (5-FU) modulated by a fixed dose of levo-folinic acid (LFA) 250 mg/m2 on day 2, recycling every two weeks, and to have preliminary evidence of activity of this combination in pretreated advanced colorectal cancer patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
461-8
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:10847467-Adult,
pubmed-meshheading:10847467-Aged,
pubmed-meshheading:10847467-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10847467-Carcinoma,
pubmed-meshheading:10847467-Colonic Neoplasms,
pubmed-meshheading:10847467-Dose-Response Relationship, Drug,
pubmed-meshheading:10847467-Drug Administration Schedule,
pubmed-meshheading:10847467-Drug Interactions,
pubmed-meshheading:10847467-Female,
pubmed-meshheading:10847467-Fluorouracil,
pubmed-meshheading:10847467-Humans,
pubmed-meshheading:10847467-Infusions, Intravenous,
pubmed-meshheading:10847467-Leucovorin,
pubmed-meshheading:10847467-Male,
pubmed-meshheading:10847467-Middle Aged,
pubmed-meshheading:10847467-Organoplatinum Compounds,
pubmed-meshheading:10847467-Quinazolines,
pubmed-meshheading:10847467-Rectal Neoplasms,
pubmed-meshheading:10847467-Thiophenes,
pubmed-meshheading:10847467-Treatment Outcome
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Oxaliplatin and raltitrexed combined with leucovorin-modulated 5-fluorouracil i.v. bolus every two weeks: a dose finding study in advanced previously treated colorectal carcinoma. Southern Italy Cooperative Oncology Group.
|
|
pubmed:affiliation |
Medical Oncology A, National Tumour Institute, Naples, Italy. pcomella@sirio-oncology.it
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase I
|
